Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy

Journal of Cellular Biochemistry

Volumn 99, Issue 3, 2006, Pages 679-689

  Resnick Silverman, Lois ^a   Manfredi, James J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

DNA binding; Gene expression; p53; Target site selectivity; Transcription; Tumor suppressor

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELLULAR DISTRIBUTION; DNA BINDING; DNA CONFORMATION; DNA DAMAGE; DNA REPAIR; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOTOXICITY; PRIORITY JOURNAL; PROTEIN PROCESSING; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749459941     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20925     Document Type: Article

References (50)

1. Appella E, Anderson CW. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268:2764-2772.
2. Ashcroft M, Kubbutat MH, Vousden KH. 1999. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19:1751-1758.
3. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89:1175-1184.
4. Ayed A, Mulder FA, Yi GS, Lu Y, Kay LE, Arrowsmith CH. 2001. Latent and active p53 are identical in conformation. Nat Struct Biol 8:756-760.
5. Bargonetti J, Manfredi JJ. 2002. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14:86-91.
6. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7:2565-2574.
7. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8:1243-1254.
8. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288.
9. Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B, Bracco L. 1999. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18:551-557.
10. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. 2004. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010-1014.
11. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355.
12. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S. 2002. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4:11-19.
13. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. 1979. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 76:2420-2424.
14. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
15. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. 1992. Definition of a consensus binding site for p53. Nat Genet 1:45-49.
16. Espinosa JM, Emerson BM. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8:57-69.
17. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560-564.
18. Friedlander P, Haupt Y, Prives C, Oren M. 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16:4961-4971.
19. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR. 2002. A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99:937-942.
20. Fuchs B, O'Connor D, Fallis L, Scheidtmann KH, Lu X. 1995. p53 phosphorylation mutants retain transcription activity. Oncogene 10:789-793.
21. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866-2871.
22. Gu W, Roeder RG. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
23. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, Will H, Schmitz ML. 2002. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4:1-10.
24. Iwabuchi K, Li B, Massa HF, Trask BJ, Date T, Fields S. 1998. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J Biol Chem 273:26061-26068.
25. Kaeser MD, Iggo RD. 2002. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99:95-100.
26. Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, Friedman P, Prives C, Vogelstein B. 1991. DNA abnormally in vitro. Oncogene 6:131-136.
27. Ko LJ, Prives C. 1996. p53: Puzzle and paradigm. Genes Dev 10:1054-1072.
28. Lane DP, Crawford LV. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263.
29. Lane DP, Hupp TR. 2003. Drug discovery and p53. Drug Discov Today 8:347-355.
30. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827.
31. Ludwig RL, Bates S, Vousden KH. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16:4952-4960.
32. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148.
33. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, Harel-Bellan A. 2002. Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99:14849-14854.
34. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. 2003. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11:577-590.
35. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102:849-862.
36. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M, Nakamura Y. 2001. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 8:85-94.
37. Oren M, Levine AJ. 1983. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc Natl Acad Sci USA 80:56-59.
38. Pellegata NS, Cajot JF, Stanbridge EJ. 1995. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. Oncogene 11:337-349.
39. Prives C, Hall PA. 1999. The p53 pathway. J Pathol 187:112-126.
40. Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK. 2002. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 21:7901-7911.
41. Reczek EE, Flores ER, Tsay AS, Attardi LD, Jacks T. 2003. Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol Cancer Res 1:1048-1057.
42. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. 1998. DNA damage activates p53 through a phosphorylation- acetylation cascade. Genes Dev 12:2831-2841.
43. Saller E, Tom E, Brunori M, Otter M, Estreicher A, Mack DH, Iggo R. 1999. Increased apoptosis induction by 121F mutant p53. EMBO J 18:4424-4437.
44. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X. 2001. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8:781-794.
45. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. 2000. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14:289-300.
46. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu BA. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
47. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. 2001. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159.
48. Vousden KH. 2002. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602:47-59.
49. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, Maruta H, Kaul SC. 2000. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 60:6818-6821.
50. Wang W, Takimoto R, Rastinejad F, El-Deiry WS. 2003. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23:2171-2181.